Geron Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for oncology, with a primary focus on hematologic myeloid malignancies. The company's core business model centers around its proprietary, first-in-class telomerase inhibitor, RYTELO (imetelstat). RYTELO is approved in the United States and the European Union for treating adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron is also advancing imetelstat through a pivotal Phase 3 clinical trial (IMpactMF) for the treatment of relapsed or refractory myelofibrosis, as well as conducting early-stage trials for other hematologic malignancies such as acute myeloid leukemia (AML). The company generates revenue primarily through the commercial sales of RYTELO, which saw significant growth following its regulatory approvals. Geographically, Geron operates primarily in the United States, where its corporate and commercial functions are based, while engaging with global regulatory bodies and clinical sites across North America, Europe, and Asia. In a highly competitive oncology market, Geron distinguishes itself through its specialized focus on telomerase inhibition, aiming to reduce the proliferation of malignant stem and progenitor cells in the bone marrow.
